(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 31 December 2003 (31.12.2003)

PCT

(10) International Publication Number WO 2004/000993 A2

(51) International Patent Classification7:

C12N

(21) International Application Number:

PCT/CA2003/000897

(22) International Filing Date:

13 June 2003 (13.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2,391,118


21 June 2002 (21.06.2002) CA


(71) Applicants (for all designated States except US): UNI-VERSITE DU QUEBEC A MONTREAL [CA/CA]; Succursale Centre-Ville, Case Postale 8888, Montreal, Quebec H3C 3P8 (CA). CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL [CA/CA]; Centre de Recherche Hotel Dieu, Pavillon Masson, 3850 Rue St-Urbain, Montreal, Quebec H2W 1T7 (CA).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PAQUIN, Joanne [CA/CA]; 10151 Georges-Baril, Montréal, Québec H2C 2M9 (CA). GUTKOWSKA, Jolanta [CA/CA]; 139 Avenue Appin, Ville Mont-Royal, Quebec H3P 1V6 (CA). DANALACHE, Bogdan, A. [RO/CA]; 4555 St. Kevin, App. 306, Montreal, Quebec H3T 1J1 (CA). JANKOWSKI, Marek [CA/CA]; 5155 West Broadway, Montreal, Quebec H4V 2A1 (CA).
- (74) Agents: SHAHINIAN, Serge, S. et al.; SMART & BIGGAR, 1000 de la Gauchetiere Street West, Suite 3400, Montréal, Québec H3B 4W5 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,

[Continued on next page]

(54) Title: OXYTOCIN AS CARDIOMYOGENESIS INDUCER-AND USES THEREOF





(57) Abstract: The invention relates to oxytocin and oxytocin-related compounds and functional derivatives thereof, and uses thereof to induce differentiation of a non-cardiomyocyte (e.g. a stem/progenitor cell) to a cardiomyocyte. The invention further relates to the methods of prevention or treatment of conditions characterized by or associated with a cardiomyocyte loss or deficiency, by administration of oxytocin or an oxytocin-related compound or a functional derivative thereof to a subject, or via the administration/transplantation of a cell differentiated ex vivo by a method of the invention. The invention further relates to methods, uses, commercial packages and culture media relating to such differentiation and prevention/treatment.